Green tea with plenty of bioactive phytochemicals may have a direct impact on reduced risk and treatment of gastric cancer, some researchers suggested.
Gastric cancer is a medical condition characterized by uncontrollable growth of cells in the gastric tissues. At the late stage, the cancerous cells may infect other organs and tissue a distance away from the original site
Green tea, a precious drink processes a number of health benefits known to almost everyone in Asia and the Western world. However, as yin in nature herbal medicine or food, long-term injection of large amounts may obstruct the balance of yin-yang, inducing "excessive yin syndrome" or "yang vacuity syndrome" including weakened immunity and painful case of GERD,... according to traditional Chinese medicine's Yin-Yang theory.
According to medical literature published online, in vascular endothelial growth factor (VEGF) over expression in the formation of new blood vessels to provide nutrients and fluids for the survival of gastric cancer, application of green tea (-)-Epigallocatechin-3-gallate (EGCG) restricted the pro-inflammatory cytokine interleukin-6 (IL-6) induced VEGF in stimulated signal protein in transmitted alternated DNA transcript and activated suppression of anti-cell apoptosis transcription 3 (Stat3).
Oral administration of green tea extract decreased levels of IL-6, and VEGF overexpression in doses depending manner.
Compared to healthy individuals, IL-6, VEGF expression was found to increase more than 2.4-fold in patients with gastric cancer.
In fact, the chemical compound exhibited anti-cancer progressive activity by blocking the process of a complex sequence of VEGF expression in transferring faulty DNA transcription to signal the proliferation of cancer cells through mRNA in protein synthesis.
In other words, green tea inhibited the progression of cancer development induced by overexpression of vascular endothelial growth factor (VEGF) was total depended on EGCG's DNA binding activity and inhibition of Stat proteins in differentiated cytoplasm into the nucleus, the important step in the initiation of cancer progression.
Further analysis, according to experiments in vitro and in vitro, EGCG also expressed a significant effect in the reduced IL-6 properties in stimulated vascular endothelial cells in promoted cancer cell proliferation and formation.
After taking into account other confounders, Dr. Zhu BH, the lead author said, "EGCG inhibits IL-6-induced VEGF expression and angiogenesis via suppressing Stat3 activity in gastric cancer, which has provided a novel mechanistic insight into the anti-angiogenic activity of EGCG".
Additionally, researchers in further illustration of the effect of EGCG (0, 5, 10, 25, or 50 μmol/L), in human gastric cancer cells (AGS) caused by IL-6 (50 μg/L) suggested that interleukin 6 (IL-6) overexpression not only significantly increased VEGF expression in AGS gastric cancer cells, but also increased function of mRNA expression by more than 2.4 in the process to initiated tumor development, in dose depending manner.
Truly, treatment of bioactive EGCG with doses of 0, 5, 10, 25, or 50 μmol/L demonstrated therapeutic activities in reducing the released protein of VEGF to stimulate mRNA expression of the alternated transcript.
Compared to AG490, a Stat3 pathway inhibitor used for the treatment of gastric cancer, green tea EGCG blocked the sequence of transcript-transferred steps in the induced expression of pSTAT3 in the proliferation of cells and tumor tissues without causing a change in the STAT3 gene.
In 5-FU resistance of GC SGC7901/FU and MGC803/FU, gastric cancer cell lines, injection of epigallocatechin gallate (EGCG) displayed a significantly suppressed proliferation and tumor growth through reversed the 5-FU resistance of GC cells thorough inhibited the P-glycoprotein 1 (MDR1) and P-glycoprotein (P-gp) also also known as multidrug resistance proteins in transmitted transcript in obstructing cell internalization of chemotherapeutic agents and developing transporter-mediated resistance by cancer cells during anti-tumor treatments.
Taking together, green tea bioactive (-)-Epigallocatechin-3-gallate (EGCG) may be considered a potential agent in reducing the risk of angiogenesis and a secondary and adjunct treatment combined with standard chemotherapy in the treatment of gastric cancers.
Ovarian Cysts And PCOS Elimination
Holistic System In Existence That Will Show You How To
Permanently Eliminate All Types of Ovarian Cysts Within 2 Months
Back to Kyle J. Norton's Home page http://kylejnorton.blogspot.ca
Author Biography
Kyle J. Norton (Scholar, Master of Nutrients, All right reserved)
Health article writer and researcher; Over 10.000 articles and research papers have been written and published online, including worldwide health, ezine articles, article base, healthblogs, self-growth, best before it's news, the Karate GB Daily, etc.,.
Named TOP 50 MEDICAL ESSAYS FOR ARTISTS & AUTHORS TO READ by Disilgold.com Named 50 of the best health Tweeters Canada - Huffington Post
Nominated for shorty award over last 4 years
Some articles have been used as references in medical research, such as the international journal Pharma and Bio Science, ISSN 0975-6299.
Sources
(1) (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer by Zhu BH1, Chen HY, Zhan WH, Wang CY, Cai SR, Wang Z, Zhang CH, He YL. (PubMed)
(2) [(-)-Epigallocatechin-3-gallate reduces vascular endothelial growth factor expression in gastric cancer cells via suppressing activity].[Article in Chinese] by Zhu BH1, He YL, Zhan WH, Cai SR, Wang Z, Zhang CH, Chen HY.(PubMed)
(3) Reversal of 5-fluorouracil resistance by EGCG is mediated by the inactivation of TFAP2A/VEGF signaling pathway and down-regulation of MDR-1 and P-gp expression in gastric cancer by Tang H1,2, Zeng L2, Wang J2, Zhang X2, Ruan Q2, Wang J2, Cui S2, Yang D1. (PubMed)
No comments:
Post a Comment